The effect sizes reported here for major adverse cardiovascular events and cardiovascular mortality (in patients with and without recent ACS) are comparable with—if not greater than—those seen with guideline-recommended mainstays of cardiovascular therapy, such as aspirin, angiotensin-converting enzyme inhibitors, β-blockers, statins, and dual antiplatelet therapy.
Super interesting and thank you for sharing! A potential advantage of vaccination is that it does not require daily dosing (unlike hypertension medications), and of course, it has the benefit of also preventing illness. Would be interesting to see cost-effectiveness analyses for seasonal influenza campaigns.
I haven’t looked into this in detail (honest epistemic status: saw a screenshot on Twitter) but what do you think of the recent paper Association of Influenza Vaccination With Cardiovascular Risk?
Quoting from it, re: tractable interventions:
Super interesting and thank you for sharing! A potential advantage of vaccination is that it does not require daily dosing (unlike hypertension medications), and of course, it has the benefit of also preventing illness. Would be interesting to see cost-effectiveness analyses for seasonal influenza campaigns.